TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06022042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On1 two-stage abutment and one-stage abutment
Description: the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On1 two-stage abutment and one-stage abutment
Description: the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On1 two-stage abutment and one-stage abutment
Description: the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On1 two-stage abutment and one-stage abutment
Description: the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On1 two-stage abutment and one-stage abutment
Description: the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On1 two-stage abutment and one-stage abutment
Description: the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.
Study: NCT05768191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: premix insulin human isophane suspension and insulin human
Description: Sequence (Premix first, then Humulin N + Humulin R): Subjects randomized to this sequence will receive premix insulin, twice per day for 16 weeks. After the first 16 weeks, subjects will cross over to the Humulin N plus Humulin R sequence for a further treatment of 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin N plus Humulin R
Description: Sequence (Humulin N + Humulin R first, then Premix): Subjects randomized to this sequence will receive basal bolus insulin scheme with Humulin N (twice daily) and Humulin R (before meals) for 16 weeks. After the first 16 weeks, subjects will cross over to the Premix sequence for a further treatment of 16 weeks
Study: NCT05572177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asthma SMART
Description: The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.
Study: NCT06219161

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NAD3
Description: NAD3 supplement (per capsule): 344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NAD3
Description: NAD3 supplement (per capsule): 344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy)
Study: NCT06170229

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHIIT
Description: Education and High intensity Interval Training (Aerobic Exercise)~The focus of the one educational session is rationale for aerobic exercise, expected physiological effects of aerobic exercise, diet when performing an exercise program, how the knee accommodates to exercise (including potential experience of muscle soreness and how that is different from joint pain), and management of potential knee OA symptom flares.~HIIT is an aerobic exercise form. The eHITT protocol consist of eight 2-minute intervals of high intensity training (with the goal to train at a heart rate of at least 80% of HRmax) followed by 2 minutes of moderate training intensity (with the goal to train at a heart rate of at least 60% of HRmax).~There will be several types of exercise modalities for aerobic exercise available (treadmills, cross-trainers, row- and cycle ergometers) and participants may choose whichever they prefer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NEMEX-e
Description: Education and Neuromuscular Exercise~The focus of the two educational sessions is on providing knowledge of OA and treatment options to the participants, with a special focus on knee OA, diet, and exercise and its benefits. Furthermore, advice about self-management is given.~The exercises are based on neuromuscular principles to improve sensorimotor control and achieve compensatory functional stability. Sensorimotor control is the ability to coordinate muscle activity and maintain functional stability during movement allowing for joint stability during physical activity. Various positions (sitting, lying, standing) are used to achieve the desired postural activity. The overall goal is to obtain muscle control and stability in situations resembling daily life and/or more strenuous activities. The focus is on achieving good quality of the performance in each exercise with appropriate postural orientation (e.g., joint positioned appropriately in relation to each other).
Study: NCT05481398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: The wound is dressed using negative pressure wound therapy comprising of a single layer of sterile gauze followed by placement of a 18 Fr nelaton catheter and the wound further covered with 4 more layers of sterile gauze over the nelaton catheter. The wound is then covered with opsite dressing making it airtight. The nelaton catheter is attached to the wall suction port once the patient is shifted to the bed with pressure set at - 25 mm Hg.
Study: NCT05055934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314 injection
Description: SHR-1314 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05253079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subcostal transversus plane block
Description: Patient in TAP block group will receive oblique subcostal TAP while in supine position using a linear 6-13 MHz ultrasound transducer. The operator will place the ultrasound probe obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The landmarks, which included the rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin and xyphoid. The probe will be then moved laterally until the aponeurosis of the external, internal oblique, and transversus abdominis are seen, and then the probe will be moved further laterally until the transversus abdominis muscle is identified. The operator will direct the needle toward the transversus abdominis, and the local anesthetic solution will be injected after negative aspiration between the rectus abdominis and transversus abdominis muscles along the subcostal line (in-plane superomedial to inferolateral)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: Patients in ESPB group will be turned to the lateral position and receive ESPB at the level of the 7th thoracic (T7) transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T7) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution will be injected below the muscle. the procedure will be repeated on the other side
Study: NCT06527222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 500mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 1000 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ranolazine placebo twice daily
Study: NCT05365269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Automatized Lifestyle intervention
Description: Multi-behavioral; including individually-tailored, theory-based, repetitive, ipsative and normative feedback.
Study: NCT05742893

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of pragmatic and discourse test scores in the two scales.
Description: The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .
Study: NCT06543550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Implantable gestrinone
Description: 1.6mg/kg of weight of gestrinone in pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Dienogest
Description: Administered orally at 2 mg daily
Study: NCT04795076

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
Study: NCT05862883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rutan 25 mg
Description: Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 25 mg. Excipients: potato starch, calcium stearate, lactulose.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Taking basic therapy without Rutan
Study: NCT05159102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week FMS Intervention
Description: 4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) and Sports (during intervention)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week FMS Intervention
Description: 4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) and Sports (during intervention)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activities & Activity Booklets (via FitFamilies app)
Description: expected to engage in physical activity at least 3 hours per week, parent workshops provide them with resources to engage in Physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activities & Activity Booklets (via FitFamilies app)
Description: expected to engage in physical activity at least 3 hours per week, parent workshops provide them with resources to engage in Physical activity

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activities & Activity Booklets (via FitFamilies app)
Description: expected to engage in physical activity at least 3 hours per week, parent workshops provide them with resources to engage in Physical activity
Study: NCT04795076

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Infant formula
Description: Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
Study: NCT06050226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.
Study: NCT06288256

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT05122793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention offer
Description: Improvement of outcomes through lifestyle changes and improved health literacy
Study: NCT05794009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality Exercise (IVRE)
Description: The IVRE program will include aerobic exercise, muscle strengthening exercise, balance and flexibility exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Aerobic exercise, muscle strengthening exercise, balance and flexibility exercise at home.
Study: NCT05363163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gana X
Description: Injection in the deep dermis and subcutaneous layer of the buttocks on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
Study: NCT06327685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib is an oral tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib is an oral tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a nucleoside metabolic inhibitor given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a nucleoside metabolic inhibitor given intravenously.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Decitabine/Cedazuridine
Description: Decitabine/Cedazuridine is a combination medicine given orally.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Decitabine/Cedazuridine
Description: Decitabine/Cedazuridine is a combination medicine given orally.
Study: NCT05742568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Study: NCT06577649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive transcranial magnetic stimulation (rTMS)
Description: cTBS (50 Hz, 600 pulses, 80% resting motor threshold) for 40s was applied continuously as active rTMS at the face representation area of primary somatosensory cortex (S1)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (sham rTMS)
Description: A sham rTMS was applied using the same stimulation parameters as with cTBS, but using a placebo coil, which produced similar sound as the real coil.
Study: NCT04636879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive expectation AND dry needling in the upper trapezius fibers, at the most painful point
Description: The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding message.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral expectation AND dry needling in the upper trapezius fibers, at the most painful point
Description: The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative expectation AND dry needling in the upper trapezius fibers, at the most painful point
Description: The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
Study: NCT04975932

Intervention type: OTHER
Intervention: TACE+ICIs
Description: TACE plus ICIs ( with or without molecular targeted therapies)

Intervention type: PROCEDURE
Intervention: TACE
Description: TACE without combination of ICIs ( with or without molecular targeted therapies)
Study: NCT05742568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Study: NCT06176183

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic meniscus repair
Description: A traditional two-portal arthroscopic approach is utilized. The meniscal edges are examined using a probe, and any meniscal tears that are not stable are evaluated for potential repair. For meniscus repair, sutures have been made using the all-inside or outside-inside and inside-outside techniques.~If the procedure involving the addition of a fibrin clot is being carried out, a volume of approximately 60 milliliters of blood is taken and thereafter transferred into a basin. An assistant is able to stir the blood using a glass syringe for approximately fifteen minutes to ensure sufficient coagulation surrounding the syringe. After a sufficient clot has developed at the end of the syringe, a grasper is used to insert the clot through the anterolateral arthroscopy portal. The meniscal sutures are intentionally loosened to accommodate the clot in the meniscus, ensuring optimal contact with the lesion. Subsequently, the sutures are fastened and knotted.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic meniscus repair
Description: A traditional two-portal arthroscopic approach is utilized. The meniscal edges are examined using a probe, and any meniscal tears that are not stable are evaluated for potential repair. For meniscus repair, sutures have been made using the all-inside or outside-inside and inside-outside techniques.~If the procedure involving the addition of a fibrin clot is being carried out, a volume of approximately 60 milliliters of blood is taken and thereafter transferred into a basin. An assistant is able to stir the blood using a glass syringe for approximately fifteen minutes to ensure sufficient coagulation surrounding the syringe. After a sufficient clot has developed at the end of the syringe, a grasper is used to insert the clot through the anterolateral arthroscopy portal. The meniscal sutures are intentionally loosened to accommodate the clot in the meniscus, ensuring optimal contact with the lesion. Subsequently, the sutures are fastened and knotted.
Study: NCT06391593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-203 25 μg
Description: Active, ALTO-203 25 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-203 75 μg
Description: Active, ALTO-203 75 μg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator, Placebo-to-match
Study: NCT05907161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SRP+LASER (Dentsply Sirona - SIROLaser Blue)
Description: adjunct irradiation with a diode laser (Dentsply Sirona - SIROLaser Blue) intrasulcularly to all sites with PD ≥ 4mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SRP+HA
Description: adjunct hyaluronic acid (Regedent, HyaDENT Cross linked hyaluronic intrasulcularly to all sites with PD ≥ 4mm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRP
Description: non-surgical periodontal therapy (SRP) with utrasonic device and curretes
Study: NCT04734275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5718
Description: Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.
Study: NCT05729542

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrex Tightrope
Description: High-tensile strength suture syndesmosis repair

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthes Fibulink
Description: High-tensile strength suture syndesmosis repair
Study: NCT05828212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells injection
Description: CD19 CAR-T cells in the treatment of R/R neuromyelitis optica
Study: NCT00013000

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Test strategy for implementation guideline
Study: NCT05267223

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured interviews with individuals with paraplegia
Study: NCT05215379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xintilimab injection
Description: neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: neoadjuvant chemoradiation therapy
Study: NCT05143216

Intervention type: OTHER
Intervention: Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Canula)
Description: Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Cannula)

Intervention type: OTHER
Intervention: High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)
Description: High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)